ESO-L 40 by Chemisis Pharmaceuticals combines Esomeprazole (Enteric Coated) and Levosulpiride (Sustained Release) in a single capsule. This combination is used to treat gastroesophageal reflux disease (GERD) and other gastrointestinal disorders where reducing stomach acid and enhancing gut motility are beneficial.

• Esomeprazole (Enteric Coated) 40 mg: A proton pump inhibitor (PPI) that reduces the production of stomach acid, providing relief from symptoms such as heartburn, difficulty swallowing, and persistent cough. It helps heal acid damage to the stomach and esophagus, prevents ulcers, and may help prevent cancer of the esophagus.
• Levosulpiride (Sustained Release) 75 mg: An antipsychotic and prokinetic agent that enhances gastrointestinal motility by increasing the release of acetylcholine. It is used to treat symptoms of indigestion, such as bloating, nausea, and gastric discomfort.

The typical dosage is one capsule taken once daily, usually before a meal. The enteric coating of Esomeprazole ensures that it is released in the intestine, not the stomach, which enhances its effectiveness and reduces the risk of stomach irritation. Levosulpiride’s sustained-release formulation ensures a prolonged therapeutic effect. Common side effects include headache, dizziness, diarrhea, nausea, and abdominal pain. Serious side effects are rare but may include severe allergic reactions, significant changes in mood or behavior, and extrapyramidal symptoms (involuntary muscle movements). It is essential to follow the prescribed dosage and consult a healthcare provider if any severe side effects occur.